General description
Bst2 Antibody: Bst2 was first identified as a novel terminal B-cell-restricted antigen termed HM1.24 that is expressed on certain bone marrow cells as well as other tissues. The surface expression of Bst2 on fibroblast cell lines facilitated the stromal cell-dependent growth of DW34, a pre-B-cell line, suggesting that this protein is involved in pre-B-cell growth. Later experiments also showed it to be upregulated in several myeloma cells. More recently, Bst2 was identified an inhibitor of retroviral release from human cells whose activity is antagonized by the HIV-1 accessory protein Vpu. While Bst2 caused retention of virions on cell surfaces or endocytosis into Bst2-positive compartments, its depletion abolished the viral requirement for Vpu for virus release. This activity may represent a potential therapeutic strategy for the treatment of HIV/AIDS.
Immunogen
Bst2 antibody was raised against a 18 amino acid synthetic peptide near the amino terminus of the mouse Bst2.The immunogen is located within amino acids 60 - 110 of Bst2.
Application
Bst2 antibody can be used for detection of Bst2 by Western blot at 1 - 2 μg/mL. Antibody validated: Western Blot in human samples. All other applications and species not yet tested.
Physical form
Supplied in PBS containing 0.02% sodium azide.
| biological source | rabbit |
| Quality Segment | 100 |
| conjugate | unconjugated |
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| clone | polyclonal |
| form | liquid |
| species reactivity | mouse, human |
| concentration | 1 mg/mL |
| technique(s) | western blot: suitable |
| isotype | IgG |
| UniProt accession no. | Q8R2Q8 |
| shipped in | wet ice |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| Gene Information | mouse ... Bst2(69550) |
